§ 02 — Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇲🇦Morocco	🇺🇸United States
Authority & dossier
Regulatory authority	DMP / AMMPS	FDA
English submissions	No	Yes
CTD accepted	Yes	Yes
eCTD accepted	No	Yes
Reliance pathway	Available	None
Reference agencies	FDA (US), EMA, MHRA (UK), Health Canada +5	—
Lead pathway (timeline & fees) — Autorisation de Mise sur le Marché (AMM) — Standard Procedure · New Drug Application — 505(b)(1)
Pathway name	Autorisation de Mise sur le Marché (AMM) — Standard Procedure	New Drug Application — 505(b)(1)
Approval timeline	270–540 days	304–365 days
Application fee	MAD 30,000	USD 4,310,002
Annual renewal	MAD 5,000	USD 416,734
Local representative	Required	Not required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	Yes	No
Local responsible person	Yes	Yes
RP role	Each pharmaceutical establishment must employ a Pharmacien Responsable (Responsible Pharmacist) registered with the Conseil National de l'Ordre des Pharmaciens, accountable for product quality, pharmacovigilance, recall and regulatory compliance. A Pharmacien Responsable de la Pharmacovigilance is the contact for the Centre Anti-Poison et de Pharmacovigilance (CAPM).	US Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.
Accelerated pathways
Designations available	2 designations	6 designations
Examples	Reliance / Abridged — Expedited Review, Emergency Use Authorisation	Priority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3
Post-approval lifecycle
Variations framework	Variations are classified per DMP variation guidelines (broadly aligned with EU practice) into Minor (Type IA / IB — notification or prior-approval) and Major (Type II — prior-approval), and Extensions of registration. AMMPS transition is expected to further align variation classification with EU/WHO practice.	FDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.
Renewal cycle	AMM is valid for 5 years and renewable for further 5-year periods (potentially indefinite after first renewal, subject to favourable benefit/risk); renewal requires up-to-date CMC, safety, GMP and labelling information, plus payment of renewal fees.	FDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.
Pharmacovigilance	The Centre Anti-Poison et de Pharmacovigilance du Maroc (CAPM, Rabat) coordinates national ADR reporting; Morocco is a member of the WHO Programme for International Drug Monitoring (Uppsala Monitoring Centre, since 1992). MAHs / local AMM holders must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines (15 days for serious unexpected ADRs), and maintain a Risk Management Plan (RMP) for new active substances and vaccines.	Mandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Not permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	60–120 days	30–30 days
GCP standard	ICH E6(R2) GCP; Law 28-13 on Biomedical Research on Human Subjects (Loi relative à la protection des personnes participant aux recherches biomédicales); Helsinki Declaration	ICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56
Pricing & reimbursement
Price regulation	Regulated	Free pricing
Reference pricing	Yes	No
HTA required	No	No
HTA body	No formal national HTA agency; HTA capacity is being developed within the Ministry of Health and the Agence Nationale de l'Assurance Maladie (ANAM) under universal health coverage reforms.	ICER (Institute for Clinical and Economic Review) — independent, non-binding

Verdict colours indicate lower, moderate, or higher regulatory burden — they're not value judgements on a market.

Authority & dossier

Regulatory authority

MoroccoDMP / AMMPS
United StatesFDA

English submissions

MoroccoNo
United StatesYes

CTD accepted

MoroccoYes
United StatesYes

eCTD accepted

MoroccoNo
United StatesYes

Reliance pathway

MoroccoAvailable
United StatesNone

Reference agencies

MoroccoFDA (US), EMA, MHRA (UK), Health Canada +5
United States—

Lead pathway (timeline & fees) — Autorisation de Mise sur le Marché (AMM) — Standard Procedure · New Drug Application — 505(b)(1)

Pathway name

MoroccoAutorisation de Mise sur le Marché (AMM) — Standard Procedure
United StatesNew Drug Application — 505(b)(1)

Approval timeline

Morocco270–540 days
United States304–365 days

Application fee

MoroccoMAD 30,000
United StatesUSD 4,310,002

Annual renewal

MoroccoMAD 5,000
United StatesUSD 416,734

Local representative

MoroccoRequired
United StatesNot required

Local manufacturing

MoroccoNot required
United StatesNot required

GMP inspection

MoroccoRequired
United StatesRequired

MAH & local presence

Local entity required

MoroccoYes
United StatesNo

Local responsible person

MoroccoYes
United StatesYes

RP role

MoroccoEach pharmaceutical establishment must employ a Pharmacien Responsable (Responsible Pharmacist) registered with the Conseil National de l'Ordre des Pharmaciens, accountable for product quality, pharmacovigilance, recall and regulatory compliance. A Pharmacien Responsable de la Pharmacovigilance is the contact for the Centre Anti-Poison et de Pharmacovigilance (CAPM).
United StatesUS Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.

Accelerated pathways

Designations available

Morocco2 designations
United States6 designations

Examples

MoroccoReliance / Abridged — Expedited Review, Emergency Use Authorisation
United StatesPriority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3

Post-approval lifecycle

Variations framework

MoroccoVariations are classified per DMP variation guidelines (broadly aligned with EU practice) into Minor (Type IA / IB — notification or prior-approval) and Major (Type II — prior-approval), and Extensions of registration. AMMPS transition is expected to further align variation classification with EU/WHO practice.
United StatesFDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.

Renewal cycle

MoroccoAMM is valid for 5 years and renewable for further 5-year periods (potentially indefinite after first renewal, subject to favourable benefit/risk); renewal requires up-to-date CMC, safety, GMP and labelling information, plus payment of renewal fees.
United StatesFDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.

Pharmacovigilance

MoroccoThe Centre Anti-Poison et de Pharmacovigilance du Maroc (CAPM, Rabat) coordinates national ADR reporting; Morocco is a member of the WHO Programme for International Drug Monitoring (Uppsala Monitoring Centre, since 1992). MAHs / local AMM holders must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines (15 days for serious unexpected ADRs), and maintain a Risk Management Plan (RMP) for new active substances and vaccines.
United StatesMandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.

Unlicensed access

Named Patient Supply

MoroccoAvailable
United StatesAvailable

Compassionate Use

MoroccoAvailable
United StatesAvailable

Emergency Import

MoroccoAvailable
United StatesAvailable

Parallel Import

MoroccoNot permitted
United StatesNot permitted

Clinical trials

CTA approval

MoroccoRequired
United StatesRequired

Ethics approval

MoroccoYes
United StatesYes

CTA timeline

Morocco60–120 days
United States30–30 days

GCP standard

MoroccoICH E6(R2) GCP; Law 28-13 on Biomedical Research on Human Subjects (Loi relative à la protection des personnes participant aux recherches biomédicales); Helsinki Declaration
United StatesICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56

Pricing & reimbursement

Price regulation

MoroccoRegulated
United StatesFree pricing

Reference pricing

MoroccoYes
United StatesNo

HTA required

MoroccoNo
United StatesNo

HTA body

MoroccoNo formal national HTA agency; HTA capacity is being developed within the Ministry of Health and the Agence Nationale de l'Assurance Maladie (ANAM) under universal health coverage reforms.
United StatesICER (Institute for Clinical and Economic Review) — independent, non-binding